JP2009537550A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537550A5
JP2009537550A5 JP2009511089A JP2009511089A JP2009537550A5 JP 2009537550 A5 JP2009537550 A5 JP 2009537550A5 JP 2009511089 A JP2009511089 A JP 2009511089A JP 2009511089 A JP2009511089 A JP 2009511089A JP 2009537550 A5 JP2009537550 A5 JP 2009537550A5
Authority
JP
Japan
Prior art keywords
ethoxy
pharmaceutical composition
cyclosporine
cyclosporin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009511089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537550A (ja
JP5377293B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/011919 external-priority patent/WO2007136759A2/en
Publication of JP2009537550A publication Critical patent/JP2009537550A/ja
Publication of JP2009537550A5 publication Critical patent/JP2009537550A5/ja
Application granted granted Critical
Publication of JP5377293B2 publication Critical patent/JP5377293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009511089A 2006-05-19 2007-05-18 眼疾患の治療及び予防方法 Active JP5377293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80220806P 2006-05-19 2006-05-19
US60/802,208 2006-05-19
PCT/US2007/011919 WO2007136759A2 (en) 2006-05-19 2007-05-18 Method for the treatment and prevention of ocular disorders

Publications (3)

Publication Number Publication Date
JP2009537550A JP2009537550A (ja) 2009-10-29
JP2009537550A5 true JP2009537550A5 (enExample) 2010-07-01
JP5377293B2 JP5377293B2 (ja) 2013-12-25

Family

ID=37814449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511089A Active JP5377293B2 (ja) 2006-05-19 2007-05-18 眼疾患の治療及び予防方法

Country Status (12)

Country Link
US (2) US8188052B2 (enExample)
EP (1) EP2023918B1 (enExample)
JP (1) JP5377293B2 (enExample)
CN (1) CN101511357B (enExample)
AT (1) ATE502633T1 (enExample)
AU (1) AU2007254148B2 (enExample)
CA (1) CA2652662C (enExample)
DE (1) DE602007013391D1 (enExample)
DK (1) DK2023918T3 (enExample)
ES (1) ES2361635T3 (enExample)
WO (1) WO2007136759A2 (enExample)
ZA (1) ZA200810113B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) * 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2782898A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
JP5805773B2 (ja) * 2010-10-12 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンアナログ
CA2814192A1 (en) 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
WO2012123515A1 (en) * 2011-03-14 2012-09-20 Drug Delivery Solutions Limited An ophthalmic composition
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
CN105324708B (zh) 2013-06-18 2020-02-14 唯景公司 非矩形形状上的电致变色设备
US20150005186A1 (en) * 2013-06-27 2015-01-01 Jing-Feng Huang Methods and devices for classifying and managing autoimmune and inflammatory conditions
MX364310B (es) 2013-11-05 2019-04-22 Gustavo A Garcia Sanchez Método para preparar una formulación inmunosupresora.
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
KR102084341B1 (ko) * 2015-12-14 2020-03-03 요우 핑 차오 짧은 합성 펩티드 및 그의 용도
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US20200366476A1 (en) * 2019-05-17 2020-11-19 Panasonic Avionics Corporation Transient key negotiation for passenger accessible peripherals
JP2022551161A (ja) * 2019-10-12 2022-12-07 ファーサイト メディカル テクノロジー （シャンハイ） カンパニー リミテッド ネフロトキシン誘発性腎障害の処置及び予防
CN111920940B (zh) * 2020-09-16 2022-04-05 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
EP4126905A4 (en) * 2020-03-26 2024-05-29 Farsight Medical Technology (Shanghai) Co., Ltd. CYCLOPHILIN INHIBITORS AND THEIR USES
WO2021209003A1 (en) * 2020-04-15 2021-10-21 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
US11564909B2 (en) * 2020-11-30 2023-01-31 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid
WO2024245384A1 (en) * 2023-06-02 2024-12-05 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
DE69124459T3 (de) 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
WO1994022896A1 (fr) 1993-03-31 1994-10-13 Tokyo Tanabe Company Limited Ameliorant de la cholestase
WO1995003056A1 (en) 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
HUP9900405A3 (en) 1995-07-17 2001-04-28 Scynexis Inc Durham Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
CN1205220C (zh) 1998-06-12 2005-06-08 斯－凯穆公司 新颖的环孢菌素
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
BR9911724A (pt) 1998-07-01 2001-03-20 Debiopharm Sa Ciclosporina que tem um perfil de atividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
RU2223761C2 (ru) 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
MY139078A (en) 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN1984670A (zh) 2004-07-13 2007-06-20 诺瓦提斯公司 治疗阿尔茨海默病的环孢菌素
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
SG139750A1 (en) 2004-10-01 2008-02-29 Debiopharm Sa Ch Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20090214464A1 (en) 2004-12-23 2009-08-27 Beat Weidmann Compounds for flaviviridae treatment
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
CN102271688A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv的环孢菌素衍生物和核苷的组合
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2782898A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Similar Documents

Publication Publication Date Title
JP2009537550A5 (enExample)
JP2008514732A5 (enExample)
KR102279999B1 (ko) 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물
ES2540561T3 (es) N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
ES2654615T3 (es) Compuestos de carbamato para el tratamiento del trastorno bipolar
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2009504763A5 (enExample)
JP2014508804A5 (enExample)
JP2015512860A5 (enExample)
JP2012519691A5 (enExample)
JP2007520452A5 (enExample)
ES2748974T3 (es) Inhibidores de la polimerasa del virus de la hepatitis C
RU2011127079A (ru) Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
AU2017231817A1 (en) Elimination of hepatitis B virus with antiviral agents
JP2007529421A5 (enExample)
JP2013525318A5 (enExample)
WO2015092634A1 (en) 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2014182643A2 (en) Methods for treating hcv infection
JP2007505931A5 (enExample)
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
AU2019355218A1 (en) Monomer and multimeric anti-HBV agents
JP2012524110A5 (enExample)
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
JP2010514733A5 (enExample)
JP2003520208A5 (enExample)